Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

Movement Disorders

Volumn 16, Issue 4, 2001, Pages 708-713

  Rascol, O ^a   Arnulf, I ^b   Peyro Saint Paul, H ^c   Brefel Courbon, C ^a   Vidailhet, M ^b   Thalamas, C ^a   Bonnet, A M ^b   Descombes, S ^a   Bejjani, B ^b   Fabre, N ^a   Montastruc, J L ^a   Agid, Y ^b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

2 receptors; Dyskinesia; Idazoxan; L DOPA; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; EFAROXAN; IDAZOXAN; LEVODOPA; LISURIDE; PLACEBO; RAUWOLSCINE; SELEGILINE; YOHIMBINE;

ADRENERGIC RECEPTOR BLOCKING; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSKINESIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; NAUSEA; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TACHYCARDIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; IDAZOXAN; LEVODOPA; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PILOT PROJECTS;

EID: 0035412888     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1143     Document Type: Article

References (38)

1. Rascol O. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Mov Disorders 1999;14:19-32.
2. Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol 2000;47:S179-S188.
3. Brefel-Courbon C, Thalamas C, Peyro Saint Paul H, Senard JM, Montastruc JL, Rascol O. α2 adrenoceptor antagonists: A new approach of Parkinson's disease. CNS Drugs 1998;10:189-207.
4. Gomez-Mancilla B, Bédard PJ. Effect of non dopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
5. Henry B, Plowright A, Fox SH, et al. Alpha-2-adrenergic receptor antagonists reduce symptoms in animal models of L-dopa-induced dyskinesia. Soc Neurosci Abst 1997;23:742.
6. Henry B, Fox S, Peggs D, Crossman A, Brotchie J. The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances antiparkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disorders 1999;14: 744-753.
7. Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bedard PJ. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Arch Pharmacol 2000;361:181-186.
8. Mavridis M, Colpaert FC, Millan MJ. Differential modulation of (+) amphetamine-induced rotation in unilateral substancia nigra-lesioned rats by α1 as to compared to α2 agonists and antagonists. Brain Res 1991;562:216-224.
9. Chopin P, Colpaert FC, Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther 1999;288:798-804.
10. Bezard E, Brefel-Courbon C, Tison F, Peyro-Saint-Paul H, Ladure P, Rascol O, Gross CE. Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:1237-1346.
11. Peyro-Saint-Paul H, Durif F, Pollak P, Bonnet AM, et al. Short term oral administration of idazoxan in mild stable parkinsonian patients treated with L-dopa. Therapie 1995;suppl 1:172.
12. Ruzicka E, Ladure P, Roth J, Jech R, Mecin P, Peyro-Saint Paul H. Efficacy and safety of efaroxan, an alpha-2 adrenoceptor antagonist, in Parkinson's disease: an oral short-term study. Move Disord 1997;12:S123.
13. Manson AJ, Iakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:336-337.
14. Lees AJ. The relevance of Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51:144-147.
15. Fahn S, Elton R, and Unified Parkinson's Disease Rating Scale Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, editors. Recent developments in Parkinson's disease. New York: Macmillan, 1987;2:153-163.
16. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
17. Durif F, Vidhailet M, Roche C, Bonnet AM, Agid Y. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1996;48:658-662.
18. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
19. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
20. Melamed E, Olanow CW, Nutt JG, Lang AE. Dyskinesias assessment workshop: reports from the working groups. Mov Disord 1999;14:69-73.
21. Adler I. A new look at geometry. New York: The John Day Company; 1966.
22. Widner H, Tetrud J, Rehngrona S, et al. Bilateral fetal mesencephalic graphting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP). N Engl J Med 1992;327:1556-1563.
23. Widner H, Defer G, Levivier M, NIPD Group. Ratings of dyskinesias in the CAPSIT-Program. Mov Disord 1998;13:S94.
24. Hortsink MW, Zijlmans JCM, Pasman JW, Berger HJC, van't Hof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neuro Neurosurg Psychiatry 1990;53:224-226.
25. Charney DS, Heninger GR, Redmond DE. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 1983;33:19-29.
26. Marsden CD. Emotion and movement. In: Garlick D, editor. Proprioception, posture and emotion. Univ NSW, Sydney: Committee in postgraduate medical education; 1982. p 185-194.
27. Senard JM, Durrieu G, Berlan M, Estan L, Valet P, Tran MA, Garrigues M, Montastruc JL. Abscence of arterial hypertension despite chronic plasma noradrenaline elevation: evidence for down-regulation of alpha-adrenoceptors. A case report. Fundam Clin Pharmacol 1991;5:291-298.
28. Rascol O, Sieardzan K, Peyro-Saint-Paul H, et al. Efaroxan, an alpha-2 antagonist, in the treatment of Progressive Supranuclear Palsy. Mov Disord 1998;13:673-676.
29. Schuh LA, Bennett JP. Suppression of dyskinesias in advanced Parkinson's disease: continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550.
30. Werhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chasz TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
31. Bousquet P. Imidazoline receptors: from basic concepts to recent developments. J Cardiovasc Pharmacol 1995;26 (suppl 2):S1-S6.
32. Tesson F, Limon-Boulez I, Urban P, et al. Localization of I2-imidazoline binding sites on monoamine oxidases. J Biochem 1995;270:9856-9861.
33. Regunathan S, Reis DJ. Imidazoline receptors and their endogenous ligands. Ann Rev Pharmacol Toxicol 1996;36:511-544.
34. Gaspar P, Berger B, Febvret A, Vigny A, Henry JP. Catecholamine innervation of the human cerbral cortex as revealed by comparative immunohistochemistry of tyrosine hydroxylase and dopamine-beta-hydroxylase. J Comp Neurol 1989;279:249-271.
35. Gaspar P, Duyackaerts C, Alvarez C, Javoy-Agid F, Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol 1991;30:365-374.
36. Donaldson I, Dolphin A, Jenner P, Marsden CD, Pycock C. The roles of noradrenaline and dopamine in contraversive circling behaviour seen after unilateral electrolytic lesions of the locus coeruleus. Eur J Pharmacol 1976;39:179-191.
37. Bowes MP, Peters RH, Kernan WJ, Hopper DI. Effects of yohimbine and idazoxan on motor behaviors in male rats. Pharmacol Biochem Behav 1992;41:707-713.
38. Chopin P, Pellow S, File SE. The effects of yohimbine on exploratory and locomotor behavior are attributable to its effects at noradrenaline and not at benzodiazepine receptors. Neuropharmacology 1986;25:53-57.